Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian Indices Open Flat
Mon, 19 Sep 09:30 am

Major Asian stock markets have opened the day on a positive note with the stock markets in Taiwan and China are trading higher by 2.6% and 0.6% respectively. Benchmark indices in Europe and the US ended their previous session in red with benchmarks indices in US ending the day lower by 0.5%. The rupee is trading at 66.88 per US$.

Indian stock markets have opened the day on a flattish note. The BSE Sensex is trading marginally higher by 38 points (up 0.1%) and the NSE Nifty is trading higher by 8 points (up 0.1%). Both, BSE Mid Cap and BSE Small Cap are trading higher by 0.5% each.

Barring information technology, major sectoral indices have opened the day on a positive note. Stocks from banking sector are witnessing maximum buying interest.

As per an article in Livemint, Lupin is looking for opportunities for an acquisition in the domestic market. The company has made significant number of acquisitions in the overseas market in the preceding two years. This includes the likes Gavis Pharmaceutical acquired for a sum of US$ 880 million and Shionogi's product portfolio in Japan.

Now it is looking out for opportunities in the domestic market, considering that pharmaceutical market in India is expected to grow to US$ 55 billion in 2020 from the current US$ 20 billion as per reports.

Reportedly, according to management the acquisition in the domestic space will be done for the therapies in which the company has lower market share or little presence. This will enable the company to diversify its presence across varied therapies.

India business currently accounts for 29% of the company's revenues. Lupin is currently ranked 8th in the domestic Pharmaceutical market. It is the leading player in the Anti-TB segment. Further, the company also derives major portion of its revenues from respiratory, anti-diabetic and cardiology segments in the domestic market.

Thus one will have to look into as to which new therapies Lupin will enter. The stock is trading marginally higher by 0.1%.

In another news update, a committee headed by the chief economic advisor, Mr Arvind Subramanian, has recommended increasing the minimum support price of tur and urad dal by 20%.

Reportedly, the committee stated that the MSP of the two pulse variety should be increased to Rs 60 kg from the prevailing Rs 50 kg. The increase in MSP if accepted will help the farmers with increased income. This in-turn can spurt the rural consumption which has remained subdued since a while now. Further, a normal monsoon this year is expected to bring in bumper production of agriculture produce of pulses in India.

Recently, there is a flood of Initial Public Offer's (IPO) hitting the market. Confused as to which one's to apply and which ones to avoid? Our recent edition of The 5 Minute WrapUp offers two ways to think about IPOs and explains how to profit from them.

Further, to help you approach the big IPOs as an enterprising investor would, we are preparing special handbook for IPO Investing. Watch this space to know how you could access it...

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Indian Indices Open Flat". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jan 16, 2018 (Close)